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Mutations in the leucine-rich repeatkinase2 (LRRK2) gene cause late-onset Parkinson’s disease (PD). Emerging
evidence suggests a role for LRRK2 in the endocytic pathway. Here, we show that LRRK2 is released in extracel-
lular microvesicles (i.e. exosomes) from cells that natively express LRRK2. LRRK2 localizes to collecting duct
epithelial cells in the kidney that actively secrete exosomes into urine. Purified urinary exosomes contain
LRRK2 protein that is both dimerized and phosphorylated. We provide a quantitative proteomic profile of
1673 proteins in urinary exosomes and find that known LRRK2 interactors including 14-3-3 are some of the
most abundant exosome proteins. Disruption of the 14-3-3 LRRK2 interaction with a 14-3-3 inhibitor or through
acute LRRK2 kinase inhibition potently blocks LRRK2 release in exosomes, but familial mutations in LRRK2 had
no effect on secretion. LRRK2 levels were overall comparable but highly variable in urinary exosomes derived
from PD cases and age-matched controls, although very high LRRK2 levels were detected in some PD affected
cases. We further characterized LRRK2 exosome release in neurons and macrophages in culture, and found that
LRRK2-positive exosomes circulate in cerebral spinal fluid (CSF). Together, these results define a pathway for
LRRK2 extracellular release, clarify one function of the LRRK2 14-3-3 interaction and provide a foundation for
utilization of LRRK2 as a biomarker in clinical trials.
INTRODUCTION
Missense mutations in the Leucine-Rich Repeat Kinase 2
(LRRK2) gene cause late-onset Parkinson’s disease (PD) in
both autosomal-dominant disease transmitting families (1,2)
and sporadic late-onset disease populations (3–5). In addition
to linkage to PD through genome-wide association studies (6),
LRRK2 genetic variants impose susceptibility risks to
inflammation-linked diseases that include Crohn’s disease and
mycobacterium infection (7,8). The LRRK2 gene encodes a
protein with a unique multi-domain composition, including
functional GTPase and protein kinase domains, and missense
mutations that cause PD alter these enzymatic activities (9,10).
Understanding the function of LRRK2 may provide insight
into pathogenic mechanisms as well as uncover particular
targets for disease-modifying therapeutics.
LRRK2 expression in mammals is widely distributed in many
cell types, but particularly enriched in the kidney and in activated
macrophages of the innate immune system (11–13). In the brain,
LRRK2 expression is relatively modest and includes medium
spiny neurons in the striatum that form striosomes (14). On a sub-
cellular level, LRRK2 associates with a number of vesicle types
and with intraluminal vesicles within multivesicular bodies
(MVBs) (15–18). Assignment of LRRK2 function within the
endocytic pathway has been suggested (15–25), with recent evi-
dence for action in retrograde vesicle trafficking from endo-
somes to the trans-Golgi network (26), and for modifying
chaperone-mediated autophagy (27). Over expression of the
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late-endosome GTPase Rab7 and related Rab7 isoforms rescue
LRRK2-mediated phenotypes in neurons (26), while RNAi
knockdown of ArfGAP1, a protein associated with vesicle bio-
genesis, also rescues LRRK2 phenotypes in neurons (24).
Thus, compelling experimental evidence suggests that inter-
action in the endocytic pathway is at the heart of LRRK2 func-
tion in health and disease, yet it is not known how LRRK2
interacts in this pathway and whether there are other aspects to
LRRK2 interaction with vesicles that have not been considered.
Elevated LRRK2 kinase activity is linked to PD susceptibility
since the most common pathogenic LRRK2 mutation G2019S
increases kinase activity 3-fold in most assays (9,10,28,29),
and overall LRRK2 subcellular localization has been described
as exquisitely sensitive to acute LRRK2 kinase inhibition (30).
LRRK2 interaction with 14-3-3 proteins appears to be one of
the main modulators of LRRK2 subcellular localization (30),
consistent with the notion that 14-3-3 isoforms principally func-
tion by modulating cell localization of binding partners.
However, there are no known physiological roles described for
the 14-3-3 LRRK2 interaction or impact that 14-3-3-mediated
localization may have on LRRK2 functionality, particularly
within the endocytic pathway.
Here, we find that LRRK2 is secreted from intra-luminal vesi-
cles from MVBs (i.e. exosomes) from a variety of cells where
LRRK2 is natively expressed, including cells in the kidney,
brain and immune system. LRRK2 can be readily detected
through purification of exosomes from urine or cerebral spinal
fluid (CSF) in clinical populations, or through exosomes from
cell culture media. We find that a major role for the 14-3-3
LRRK2 interaction may be the regulation of LRRK2 association
with late endosomes and uptake into MVBs with a subsequent
extracellular release of LRRK2 protein via exosome secretion.
These studies elucidate a new component to LRRK2 functional-
ity in the endocytic pathway and open the door for
LRRK2-targeted biomarker and clinical trial studies through
characterization of a convenient source for LRRK2 protein
(e.g. urine and CSF). Future studies may show that direct
LRRK2 action extends to cells that lack autonomous LRRK2 ex-
pression through the process of exosome uptake and incorpor-
ation of active LRRK2 protein.
RESULTS
Identification of LRRK2 in exosomes
LRRK2 action in the endocytic pathway may include aspects of
lysosomal and autophagy-mediated degradation, receptor recyc-
ling, and vesicle budding. Evidence of LRRK2 association with
MVBs, the obligate source of exosomes, was observed previous-
ly (16). Our past studies demonstrated that the highest expression
of endogenous LRRK2 in mice is in the kidney (13), and the
kidneys are known to secrete high quantities of exosomes into
urine. To test whether LRRK2 can be secreted in urinary exo-
somes, we isolated a 100K × g pellet (P100) into lysis buffer to-
gether with an equivalent-volume concentrated supernatant
from healthy human subjects and measured the LRRK2
protein content via western blot (Fig. 1A). LRRK2 was present
at an approximate concentration of 1 pg/ml of urine, and all of
the LRRK2 protein localized to the P100 (exosome) fraction.
Exosomes are organelles that maintain the orientation of the
proteins from the parental cells, so that extracellular proteins
or extracellular protein domains remain extra-exosomal,
whereas cell cytosolic proteins are encapsulated within the
exosome (31). A trypsin-sensitivity assay demonstrated that
the addition of triton-X 100 detergent to break the vesicles was
required for proteolytic digestion of LRRK2, suggesting that
LRRK2 is localized within exosomes (Fig. 1B). The LRRK2
binding partner 14-3-3 was also sensitive to trypsin degradation
in the presence of a detergent. In contrast, CD9 is known to be
present in a large trans-luminal protein complex within the
plasma membrane that was resistant to trypsin digestion
whether or not the detergent was added.
Next, the P100 fraction was separated on an iodixanol density
gradient and LRRK2 was found to float in the same fraction as
the canonical exosome proteins Alix and TSG101 (Fig. 1C), sug-
gesting that LRRK2 specifically resides within exosomes. CD9 is
a transmembrane protein that is abundant in plasma membrane-
derived vesicles that traffic to MVBs (32,33). We found that
CD9 diffusely spreads across the high-density fractions, with
the highest concentration in the exosome-containing fraction.
Under native (non-crosslinkedor dehydrated) conditions, the exo-
somes were perfectly spherical with intra-exosome puncta com-
posing a dense vesicle core, as visualized using cryo-electron
microscopy(EM,Fig.1D).WelocalizedLRRK2immunoreactiv-
ity to isolated exosomes using a super-resolution technique (sti-
mulated emission depletion microscopy) and found structures
also of 100 nm in size with LRRK2 protein primarily concen-
trated in the exosome core (Fig. 1E). CD9 has been previously
used in fluorescent and immunoaffinity approaches to purify exo-
somes, but we found complete exclusion of LRRK2 immunoreac-
tivity in CD9-positive exosomes via immunofluorescence in
diluteexosomepreparations (Fig.1F). Incontrast,LRRK2partial-
ly co-localized to TSG101-enriched exosomes, although exam-
ples of TSG101-positive exosomes with weak or no detectable
LRRK2 expression could also be observed. As CD9 is a ubiqui-
tously expressed plasma membrane protein, this could indicate
that the intracellular source of LRRK2-positive exosomes could
be distinct from plasma membrane-derived exosomes.
Both LRRK2 dimerization and phosphorylation are activities
that have been linked to LRRK2 kinase activity (34,35). To
assess LRRK2 dimerization, urinary exosomes were resuspended
in buffer containing the non-ionic detergent triton X-100 and
lysates analyzed by native-PAGE (Fig. 1G). Urinary exosome
LRRK2 migration was identical to that of endogenous and
kinase-active LRRK2 isolated from cell cytosols (34). Low
amounts of LRRK2 in preparations without detergent treatment
were likely due to exosome breakage during processing, but
show that the detergent did not alter the migration pattern of
LRRK2 in native gels. To measure LRRK2 phosphorylation,
10 mg of total protein from exosomes was compared with 10 mg
of total protein isolated from low-post-mortem interval human
brain cerebral cortex (brain samples described previously for
LRRK2 expression (36)), together with 1 ng of recombinant
LRRK2 protein derived from HEK-293T cells (Fig. 1H). The re-
combinant protein isknown to be heavilyphosphorylated at serine
935 (pS935) (10). pS935 levels were comparable between recom-
binant kinase-active LRRK2 and urinary exosome-derived
LRRK2. In comparison, much lower levels of total and pS935
LRRK2 were detected in human brain.
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These results demonstrate LRRK2 can be readily measured
from urinary exosomes, and that LRRK2 protein in exosomes
derives from the cell cytosol, either captured in vesicles that
fuse with MVBs, or packaged during the inward internalization
of vesicles fusing with MVBs. Although LRRK2 protein con-
centration is appreciable in urinary exosomes, the overall
levels are not sufficient to directly assess LRRK2 kinase activity
with any described kinase activity assay.
Localization of LRRK2 to kidney luminal tubule cells
and characterization of urinary exosome proteomes
The sources of urinary exosomes are not fully understood, al-
though the kidney is thought to be the major contributor (37).
Staining for LRRK2 in healthy rat kidneys revealed intense
LRRK2 expression in virtually all segments of the outer and
inner collecting duct epithelium, with reactive cells directly
abutting luminal spaces (Fig. 2A). In contrast, rat LRRK2 KO
kidneys are non-reactive under identical staining conditions,
albeit with minor nonspecific reactivity observed in a subset of
nuclei (Fig. 2B). Since the collecting duct epithelium cells spe-
cifically are hypothesized to be contributors toward the urinary
exosome pool, these results explain in part the source of
LRRK2 in urinary exosomes.
It is possible that LRRK2 protein interactors in exosomes may
chaperone and control LRRK2 vesicular association. Although
several urinary exosome proteomic studies have been performed,
these have been qualitative assessments that have not capitalized
on recent and dramatic improvements in the proteomic technol-
ogy. To quantitatively measure the exosome proteome, urinary
exosomes were pooled from six healthy controls, and the resultant
exosomes were split into six equal fractions that were labeled with
tandem isobaric mass tags and analyzed by long-column multi-
dimensional protein identification (TMT-MudPIT). Five two
hundred and sixty-eight peptides were identified and quantifiable
that corresponds to 1673 protein identifications (Supplementary
Material, Database 1). Of the 1673 proteins, 965 mapped to
unique GeneGO objects with assigned function, and the GO
process ‘cellular component organization’ was significantly
enriched, owing to the high concentration of components of the
actin cytoskeleton and known vesicle components [false discov-
ery rate (FDR)-adjustedP ¼ 5.2× 10241]. A number of proteins
associated with neurodegenerative diseases were identified in
exosomes besides LRRK2, such as DJ-1, ApoE and Nerprelysin.
Figure 1. Localization of LRRK2 to urinary exosomes. (A) Human urine was processed into equivalent volumes of supernatant S100 (exosome depleted), P100
(exosome enriched) or the P100 wash buffer. Recombinant LRRK2 is D970-LRRK2 (Invitrogen). (B) Ten micrograms of purified urinary exosomes, treated with
or without 200 ng trypsin, with or without 1% Triton X-100, for 5 min at 378C. n.s. is non-specific band. (C) P100 urinary exosomes separated across a density gradient
and probed for expression of the indicated protein. (D) Representative cryo- EM image, scale bar is 50 nm. (E) LRRK2-fluorescent imaging in urinary exosomes
visualized by STED microscopy, scale bar is 500 nm. (F) Fluorescent co-labeling of LRRK2 (green) together with TSG101 or CD9. Arrows indicate positive
co-localization, scale bar is 2 mm.(G) Blue NativePAGE of LRRK2protein frompurified urinaryexosomes, treated with or without1% Triton X-100. (H) Comparison
of relative LRRK2 expression and phospho-serine 935 in 10 mg purified urinary exosomes with 10 mg of protein lysate from human brain (frontal cortex), or 1 ng of
recombinant LRRK2 isolated from HEK-293 T cells.
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LRRK2-interacting proteins, including 14-3-31 (Supplementary
Material, Fig. S1), HSP70/90, ezrin/moesin/ radixin, and Rab7,
were all identified at levels comparable with the most abundant
exosome proteins (Fig. 2C). Despite previous studies that indicate
some of these interactors as potential kinase substrates, we were
unable to show that LRRK2 could phosphorylate any proteins
from exosome lysates (Supplementary Material, Fig. S2).
Among the urinary exosome proteins detected, several highly
expressed proteins were identified that are considered exclusive
or highly enriched in organs other than the kidney (38). These
organs include prostate, stomach, pancreas, liver and colon
(Fig. 2D), where LRRK2 expression of differing levels can
also be detected (13). Notably, we did not obtain any evidence
that brain specific proteins were present in urinary exosomes.
Thus, it is possible that LRRK2 protein in urinary exosomes ori-
ginate from these organs, in addition to the kidney.
14-3-3 Binding to LRRK2 controls LRRK2 exosome release
We and others have found that LRRK2 may be tightly bound to
heat-shock proteins and 14-3-3 chaperones that may control
LRRK2 solubility and oligomerization (10,30,39,40). We
sought to test whether interactions with these proteins may
control LRRK2 extracellular secretion. First, we determined that
HEK-293T cells transfected with LRRK2 actively secrete exo-
somes into cell culture media (Fig. 3A). While knockdown of all
14-3-3 isoforms in HEK-293T cells is difficult to accomplish, a
short-peptide inhibitor known as difopein has been developed in
HEK-293T cells that effectively acts as a pan 14-3-3 inhibitor by
blocking 14-3-3 dimerization (41). Transfection of difopein in
LRRK2-expressing HEK-293T cells resulted in a very efficient
ablation of LRRK2 binding to 14-3-3 proteins, as observed
through immunoprecipitation assays using a pan-14-3-3 antibody
(Fig. 3B). In cells expressing both LRRK2 and difopein, LRRK2
could no longer be detected in resultant exosome fractions, yet
cytosolic levels of LRRK2 and 14-3-3 (pan) remained unaltered.
Likewise, difopein treatment did not have any significant effects
on total exosome release, indicating 14-3-3 proteins are dispens-
able for exosome biogenesis and processing.
Acute LRRK2 kinase inhibition via small molecules causes a
reduction in 14-3-3 binding to LRRK2 (30). To test whether
acute kinase inhibition-mediated loss of 14-3-3 binding would
also disrupt LRRK2 release in exosomes, we first characterized
the two most potent and specific LRRK2 kinase inhibitors
Figure 2. Localization of LRRK2 in the kidney and proteomic characterization of urinary exosomes. (A) Coronal rat kidney sections from WT or (B) KO animals,
stained with LRRK2 antibody(c41-2, Epitomics) and counterstained with H&E. Scale bars for low-magnification images (left panels) are 200 mm, and 25 mm for high
magnification (rightpanels). (C) Quantitative TMT-MudPIT results for the most abundant exosome proteins in comparison to knownLRRK2protein interactors. Error
bars are SD generated by spectral counts from six differential isobaric tags. (D) Urinary exosome proteins identified by the tissue-specific gene expression and regu-
lation database.
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described. HG-10-102 (42), that is known to be a selective
LRRK2 inhibitor, and the widely utilized L2in1 compound
(35), were first defined for potency in a kinase inhibition assay
measuring LRRK2 autophosphorylation in vitro (Fig. 3C,D).
When applied to HEK-293T cells at 1 mM concentration, these
two compounds had comparable effects in reducing 14-3-3
(pan) binding to LRRK2 and reducing LRRK2 release in exo-
somes (Fig. 3E). Unexpectedly, treatment with L2in1, a known
inhibitor of ERK5, and possibly Aurora A and CHK2, also
blocked overall exosome release in HEK-293T cells, as deter-
mined by lower levels of TSG101 (Fig. 3E) and other markers
evaluated such as Alix and CD9. Over expression of 14-3-31,
the most abundant 14-3-3 isoform identified in urinary exosomes
(Supplementary Material, Fig. and Database 1), restored 14-3-3
binding to LRRK2 and exosome release (Fig. 3E).
The cytosolic distribution of LRRK2 may be important for
LRRK2packaging intoexosomes.Usingimmunofluorescence lo-
calization in HEK-293T cells over-expressing LRRK2 protein,
we observe a diffuse yet punctate cytoplasmic localization of
LRRK2 Figure 4A). In cells co-expressing the small peptide difo-
pein, LRRK2 redistributes to concentrated perinuclear structures
(Fig. 4C), whereas exposure to LRRK2 kinase inhibitors renders
Figure3.LRRK2 exosome release is regulated by 14-3-3 (A) Representative cryo-EM image of exosomes purified from HEK-293 T cells expressing LRRK2 protein,
scale bar is 100 nm. (B) HEK-293 T cells expressing LRRK2 protein were co-transfected with eGFP, scrambled difopein (a control for difopein, see (41)) or difopein.
LRRK2 was immunoprecipitated and exosomes collected from culture media. (C, D) Dose-response curves measuring p1503 autophosphorylation (Alpha Screen
signal) in in vitro kinase assays at indicated drug concentrations. IC50 concentrations were calculated through non-linear regression. (E) HEK-293T cells expressing
LRRK2 were treated with the indicated drug (1 mM) or equivalent DMSO concentrations (0.01%) for 36 h. Cells were harvested into total cell lysates, LRRK2 immu-
noprecipitated and exosomes collected.
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LRRK2 to skein-like structures (Fig. 4E,F), consistent with
previous reports evaluating L2in1 exposures (30). We found
that 14-3-31 over expression rescued the normal localization of
LRRK2 (Fig. 4G,H). These results demonstrate how 14-3-3
binding to LRRK2 alters subcellular localization, where diffuse
cytoplasmic distribution correlates to extracellular secretion.
Because LRRK2 cytoplasmic distribution appears to critical-
ly mediate extracellular secretion, we next co-localized LRRK2
with the exosome marker TSG101 in HEK-293T cells that con-
stitutively secrete exosomes. While TSG101 had a discrete
vesicular-like distribution, LRRK2 was more evenly expressed
across the cytosol with rarer examples of discrete vesicle-sized
puncta, clearly distinguishing LRRK2 from a canonical vesicu-
lar protein (Fig. 5A). Some previous evidence suggests that the
G2019S mutation may alter this cytoplasmic distribution to
LRRK2-positive intracellular puncta, so we tested whether this
mutation affects LRRK2 secretion. Neither G2019S nor a
kinase-inactivating mutation altered overall LRRK2 secretion
(Fig. 5B). These results are also consistent with past data that
these alterations in LRRK2 do not affect binding to 14-3-3 pro-
teins (39).
The other protein linked to autosomal-dominant PD,
a-synuclein, can also be secreted in exosomes (43). To deter-
mine whether LRRK2 may co-exist in the same exosomes as
a-synuclein, we transiently co-expressed both proteins in
HEK-293T cells, isolated exosomes, and analyzed the compos-
ition of the structures by immunofluorescence. No examples of
co-localized exosomes were observed, suggesting that
a-synuclein and LRRK2 may derive from exosomes of diver-
gent origin. (Fig. 5C). a-Synuclein is also a binding partner for
14-3-3 isoforms, although thea-synuclein complex in exosomes
has not been described.
Quantification of LRRK2 in clinical exosome samples
We collected a cohort of late-onset PD without a family history
of disease (n ¼ 20) and age-matched control samples (n ¼ 15)
from the Movement Disorder Clinic at the University of
Alabama at Birmingham, following informed consent and insti-
tutional approval, and measured LRRK2 and 14-3-3(pan) ex-
pression relative to the canonical exosome marker TSG101.
Age between the PD and control cohort was similar at 62.8+
9.4 and 62.5+ 13.1, respectively, and the modified Hoehn and
Yahr score of the PD group was 2.2+ 0.38.
We found that both LRRK2 and 14-3-3(pan) had unexpectedly
high variability in both controls and PD, as LRRK2 levels varied
in the PD affected group by over two orders of magnitude, in con-
trast to TSG101 that showed lower variability (Fig. 6A). After ex-
clusionofoutliers fromthe series (identified withat least one order
of magnitude above or below the population average), there were
no significant differences in the expression of LRRK2 or 14-3-3 in
PD versus controls (P. 0.1, Fig. 6B and C), nor did LRRK2 ex-
pression correlate well with 14-3-3 (pan) expression (Fig. 6D).
There were no effects of age or gender on LRRK2 or 14-3-3 ex-
pression inurinaryexosomes.Highlevels ofLRRK2inexosomes,
more than 50-fold above the cohort average, were detected in one
PD-affected subject (Fig. 6E). This subject had normal quantities
of exosomes in urine and had typical late-onset PD, and we did not
identify a clinical cause for these extreme levels of LRRK2
(Fig. 6F). To determine whether LRRK2 expression in urine
changes over time, we collected urine from healthy control sub-
jects over the course of a week at different times of the day and
found that LRRK2 levels did not significantly vary within this
period of time (Fig. 6F shows one such subject, one-way
ANOVA P. 0.5). These data demonstrate the relative ease of
collection and measurement of LRRK2 in clinical samples, but
Figure 4.LRRK2 cytoplasmic localization is regulated by 14-3-3 (A–H) Repre-
sentative confocal images of HEK-293T cells expressing mKate2-tagged
LRRK2 (N-terminal tag), with cells treated with the indicated drug and/or
co-transfected with the indicated construct. Drugs were used at 1 mM concentra-
tion for 36 h.
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the data emphasize the importance of baseline measures of
LRRK2 expression due to extreme inter-sample variability.
LRRK2 exosomes secreted by macrophages
As opposed to constitutive exosome secretion in active neurons
and HEK-293T cells, other cells, such as macrophages, have
been described with strong acute regulation of exosome
release (44). We and others have found that activated macro-
phages of the periphery and brain express high levels of
LRRK2 protein that can be induced with stimulation
(11,12,45). Upon lipopolysaccharide (LPS) stimulation of
RAW 264.7 macrophage cell line that express endogenous
LRRK2 protein, we find that the exosome-associated protein
TSG101 nearly evacuates from the cell cytosol, and abundant
exosomes were released that contained high levels of LRRK2
expression (Fig. 7A). Thus, past-assessments of the magnitude
of LRRK2 induction in macrophages would be underestimates
if extracellular LRRK2 were not measured. To confirm and
expand on these results, we isolated into culture primary macro-
phages from the mouse peritoneum of LRRK2 transgenic mice
that express mouse WT-LRRK2 or G2019S-LRRK2 from
BAC transgenes. Stimulation of these cells with LPS resulted
in abundant LRRK2 secretion, but again the G2019S-mutation
had no effect on the total quantity of LRRK2 released (Fig. 7B
and C).
Due to the high levels of LRRK2 expressed in primary macro-
phages, immunofluorescence becomes possible. While LPS had a
striking effect on overall macrophage morphology from a polar-
ized cell into an amoeboid body, a more modest perinuclear
accumulation of LRRK2 and the remaining TSG101 could be
observed (Fig. 7D). We didnot notice an enhanced co-localization
between LRRK2 and TSG101 after stimulation, suggesting that
LRRK2 vesicular association is probably independent of stimula-
tion, but overt release is critically modified by stimulation.
Macrophage-derived exosomes provide an example of how
LRRK2 exosome release can be physiologically regulated.
LRRK2 exosomes in CSF and secretion by neurons
In the brain, serial sectioning confirmed that the most intense
LRRK2 staining was in the striatum, and many of the
LRRK2-positive cells were grouped into patches resembling
striosomes juxtaposed against the lateral ventricles (Fig. 8A).
We rationalized that LRRK2 may be secreted into the CSF
from these neurons and other LRRK2-positive cells in the
brain. Two samples of CSF were prepared from control subjects
and exosomes verified using cryo-EM (Fig. 8B). LRRK2 expres-
sion was determined at a concentration of 10 pg/ml of CSF in
these samples (Fig. 8C). To test whether pathogenic LRRK2
mutations affect neuronal LRRK2 exosome secretion, viral
transduction of cultured neurons resulted in high levels of
LRRK2 in exosomes, but these levels did not vary due to the
presence of pathogenic mutations (Fig. 8D,E). Within neurons,
LRRK2 occasionally localized with TSG101-positive vesicles,
particularly in dendrites (Fig. 8F). As neurons have been previ-
ously described as major sources of exosomes in the brain (46,
47), it seems likely that the source of LRRK2-positive exosomes
in the CSF derives from neurons expressing LRRK2.
Figure5.Lack of effect of LRRK2 mutations and lack of localization witha-synuclein in exosomes (A) Immunofluorescence co-localization of mKate2-LRRK2 (red
signal) with the MVB marker TSG101 using confocal immunofluorescence. A representative cell is shown. (B) LRRK2-myc, with the indicated mutation, was tran-
siently transfected into HEK-293T cells and exosomes and cytosol lysates collected 48 h after transfection. (C) Purified exosomes from HEK-293 T cells transfected
with mKate2-LRRK2 (red signal) and a-synuclein (blue signal). No overlapping blue/red signal could be observed. All data are representative of at least three inde-
pendent experiments, scale bars represent 10 mm.
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DISCUSSION
Our results define a pathway for LRRK2 secretion in exosomes
(Fig. 9). Exosomes may be recruited to MVBs through plasma
membrane-derived vesicles enriched in transmembrane plasma
proteins such as CD9 in a clathrin-dependent manner, or
through the direct uptake of late-endosomal vesicles into MVBs
(31). LRRK2 cytoplasmic association with late-endosome vesi-
cles is dependent on 14-3-3 binding. As opposed to canonical ves-
icular proteins, 14-3-3 bound LRRK2 is relatively diffuse and
soluble, and this is critical for packaging into MVBs. During the
process of vesicle uptake into MVBs, LRRK2 is likely captured
inward into invaginating late-endosomal vesicles in the cytosol
(Fig. 7). Cells can then release LRRK2-containing exosomes
after MVB docking to the plasma membrane in either a tightly
controlled manner, such as in macrophages, or a constitutive
manner, such as in HEK-293T cells, or cells may traffic
LRRK2-positive MVBs to other parts of the cell, such as along
dendrites of a neuron, for possible release at a physical proximity
different than the originating vesicle, and to a cell that does not
normally express LRRK2 protein.
LRRK2isaproteinkinaseof interestbothasapotentialdisease-
modifying target and as a window to pathogenic mechanisms im-
portant for disease susceptibilities. Strong genetic links to PD and
possibly Crohn’s disease, as well as some evidence for genetic
Figure 6.Characterization of exosomal LRRK2 in clinical populations. (A) Exosomes were isolated from urine of PD and control patients, and lysates were analyzed
by western blot in quadruplicate independent runs. The ‘pool’ value is a samplecomprised of 10%of each exosomelysate of the 20 PD and 15 control individualsmixed
together, allowing comparison of samples analyzed on different gels. (B–D) Plots showing relative LRRK2 expression normalized to TSG101 expression; data points
of each subject are the mean of four independent runs, with removal of subject outliers. Error bars are SEM,and the horizontal line is the cohortmean. (E) Titration of an
outlier PD affected subject, in comparison to the cohort geometric mean (GM) sample that has average LRRK2 and TSG101 expression. (F) Clinical summary of the
PD affected case analyzed in (E). (G) Urinary exosomes collected from a neurologically normal individual over the course of 1 week, and analyzed for LRRK2 and
TSG101 expression.
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susceptibility to mycobacterium infection, suggest LRRK2 action
in several cell types. Since pathogenic LRRK2 mutations in PD
are autosomal dominant and may increase kinase activity,
LRRK2 kinase inhibitors are under development for clinical
trials. One problem with past clinical trials, such as a recent trial
in PD (PRECEPT) with mixed-lineage kinase inhibitors (48), is
that confirmation of kinase inhibition in subjects was not
achieved. Our findings here show that peripheral LRRK2 is
readily accessible in urinary exosomes and also can be purified
from CSF. Based on our results, we predict that the overall
LRRK2 protein secreted into exosomes will diminish in subjects
treated with LRRK2 kinase inhibitors. Because of the strong inter-
individual variability noted in LRRK2 in urinary exosomes, it
would be essential to compare changes to baseline measurements.
Future studies are needed to address LRRK2 levels in CSF from
PD cases and controls.
As a biomarker for PD, LRRK2 expression in urinary exo-
somes was unexpectedly variable in clinical populations,
making it difficult to assess possible LRRK2 changes between
PD cases and controls. Future studies with more samples may
address some aspects of power, but it seems unlikely that the
LRRK2 measurement in urine alone would provide a valuable
diagnostic tool. Urinary and CSF exosomes as general sources
for disease biomarkers are being widely considered, and we
have developed a quantitative proteomics method for exosome
characterization. Exosomes as biologically relevant structures
are only recently understood, and in neurodegenerative disease
exosomes have been speculated as propagating toxic species
of Ab in Alzheimer’s disease (49), a-synuclein in PD
(43,50,51), SOD-1 in ALS (52) and prions in CJD (53, 54).
Here, we show that LRRK2 joins this club and opens the door
for transient LRRK2 function in cells that do not normally
express LRRK2 protein. This action may have important
effects in disease initiation or propagation and further studies ex-
ploring LRRK2 extracellular trafficking are warranted.
MATERIALS AND METHODS
See Supplemental Materials and Methods for extended protocols.
Clinical samples and exosome isolation
All studies were approved by the Institutional Review Board at
the University of Alabama at Birmingham. Urine specimens
were collected from the Movement Disorder Clinic at the Uni-
versity of Alabama at Birmingham, and CSF and brain tissue
samples were obtained from the NICHD Brain and Tissue
bank at the University of Maryland. Cell culture supernatants
and clinical samples were subjected to a differential centrifuga-
tion protocol for exosome isolation, in some cases this was fol-
lowed by a density gradient separation.
Figure 7.LRRK2 exosome secretion by macrophages (A) Macrophage cell line raw 264.7 cells were treated with or without LPS (100 ng/ml) and exosomes and cell
cytosols collected 24 h later. (B) Thioglycollate collected primary macrophages were isolated from WT or G2019S-BAC mice and exosomes and cytosol lysates
collected 24 h post-LPS transduction. (C) Quantification of exosomal LRRK2 from (B). (D,E) Confocal images of thioglycollate collected peripheral primary macro-
phages isolated from LRRK2 KO or LRRK2 BAC-transgenic mice were stained for LRRK2 protein (antibody c41-2) or TSG101. LPS (100 ng/ml) was used for 24 h
prior to fixing cells. Representative images are shown; results were typical of three independent experiments. Scale bars are 10 mm for all panels.
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Animals, cell culture and plasmids
Male WT and LRRK2 KO rats were obtained from Sigma and
used at 10–12 weeks of age. Primary neurons and macrophages
were prepared from C57BL/6J WT or LRRK2-BAC mice (JAX
strain 012467) as previously described (11, 24). All procedures
were approved by the relevant Institutional Committees.
HEK-293T cells and macrophage Raw264.7 cells were main-
tained in exosome-free media composed of DMEM with 10%
fetal-bovine serum. Cells were transfected as previously
described with WT-LRRK2, G2019S-LRRK2, D1994A kinase
dead LRRK2, 14-3-31, difopein, scrambled-difopein or eGFP,
in the pcDNA 3.1 backbone (55).
LRRK2 inhibitors and antibodies
The small molecule inhibitor HG-10-102 was synthesized
in-house according to the method previously described (42),
and L2in1 compound was a kind gift from Dr Dario Alessi. Anti-
bodies are listed in Supplemental Materials and Methods.
Immunohistochemistry, immunofluorescence, Cryo-EM
and super resolution imaging
Dissociated cells were cultured on glass coverslips and stained
for LRRK2 and other targets as previously described (34). In
all experiments, cells from LRRK2 KO animals were used to
Figure 8. LRRK2 exosome secretion by neurons and in the CSF. (A) Representative coronal section through the striatum of either WT or LRRK2 KO mice. Arrows
indicate LRRK2 positive cells in striosome-like patches present in the striatum and juxtaposed to lateral ventricles. Scale bar is 0.2 mm. (B) Representative cryo-EM
image of exosomes isolated from human CSF. Scale bar is 50 nm. (C) Western blot quantification of LRRK2 in purified CSF exosomes (D970-rLRRK2, Invitrogen).
CSF loaded onto the lane represents exosomes from the equivalent of 1 ml of CSF. (D,E) Primary cortical neurons transduced with LRRK2 adenovirus were lysed 48 h
post-transduction and exosomes purified. Quantification of relative G2019S and WT LRRK2 in exosomes secreted by neurons, normalized to cytosolic LRRK2 levels.
(F) Primary neurons cultured for 10 days in vitro, transduced with low concentrations (0.1 multiplicity of infection) of the WT-LRRK2 virus at 5 days in vitro, were
stained for LRRK2 protein (antibody N241) or TSG101. Arrow heads show co-labeled vesicles, dendrites were identified by intense MAP2 labeling (see Supplemen-
tary Material, Figs S3 and S4). White scale bars are 5 mm.
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confirm LRRK2 staining. Isolated exosome preparations were
fixed with paraformaldehyde, permeabilized with triton X-100
and stained using standard immunofluorescence protocols. For
cryo-EM, exosomes were resuspended in water, applied to a
film, plunge frozen and imaged. STED microscopy of fluores-
cently labeled exosomes was performed on a custom-built super-
resolution microscope.
Exosome proteomics
Sonicated exosome pellets were processed into trifluoroethanol,
reduced, alkylated, digested with trypsin and tandem mass tag
(TMT) labeling reagents (Thermo-Pierce) were added to the
samples. Isobaric-labeled peptides from each sample were com-
bined, purified and loaded onto a tandem long-flow SCX/C18
column, and an MuDPIT analysis was performed. Peptides
were resolved on a high-resolution mass spectrometer, with
results filtered to a 2% peptide FDR using concatenated
(forward and reverse db’s) approaches, with the requirement
of a minimum of two quantifiable peptides per reported
UniProt object. Raw data are available upon request.
Western blotting
Proteins were resuspended in Laemmli buffer and eletrophor-
esed on either 7.5% or 4–20% gradient TGX gels (BioRad)
and proteins transferred onto PVDF membranes. Blue-Native
PAGE gels were processed as previously described (10). Blots
were exposed using an Luminata HRP Substrate system (Milli-
pore) and the signal intensity recorded using an Alpha-Innotech
Fluorchem HD system or autoradiography film.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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